Funding Opportunities for Translational Research

Objective

The mission of the California Institute for Regenerative Medicine (CIRM) is to accelerate world-class science and deliver transformative regenerative medicine treatments in an equitable manner to a diverse California and world.

The objective of this initiative is to create a highly competitive opportunity for promising regenerative medicine (stem cell-based or genetic therapy) projects that accelerate the completion of translational stage activities necessary for advancement to clinical study or broad-end use for any one of the following product types:

  • TRAN1: Stem cell-based or genetic therapy therapeutic candidate 
  • TRAN2: Diagnostic (including medical imaging agents) based on stem cells, or critical for stem cell-based or genetic therapy development or use
  • TRAN3: Medical device (non-diagnostic) for a stem cell-based therapy or critical for stem cell-based or genetic therapy development or use
  • TRAN4: Novel tool that addresses a critical bottleneck to the discovery or development of stem cell-based or genetic therapy

Please see the Program Announcement for full details. 


Opportunities for TRAN funding are currently closed.

For future applicants who are interested in reading reviewer feedback on previous TRAN applications, please refer to the review summaries below. For previous versions of the TRAN Program Announcement, please refer to our Previous Funding Opportunities page.